Expansion Announcement: On August 21, 2025, Johnson & Johnson revealed plans to establish a 160,000+ square foot manufacturing facility at FUJIFILM’s biopharmaceutical site in Holly Springs, North Carolina, as part of a US$2 billion investment over ten years.
Job Creation: This initiative is expected to create approximately 120 new jobs, reinforcing Johnson & Johnson's commitment to U.S. manufacturing.
Strategic Focus on U.S. Manufacturing
Long-term Vision: The investment aligns with Johnson & Johnson's goal to produce the majority of its advanced medicines domestically while enhancing research and development in critical areas such as oncology, neuroscience, and cardiovascular disease.
Impact on Earnings: While the facility may improve production control, it is not expected to significantly affect short-term revenue catalysts, particularly with the impending loss of exclusivity for STELARA and the threat of biosimilar competition.
Financial Outlook and Growth Projections
Revenue and Earnings Forecast: Johnson & Johnson anticipates generating $104.1 billion in revenue and $22.9 billion in earnings by 2028, reflecting an annual revenue growth rate of 4.7% and a modest increase in earnings.
Fair Value Estimates: Current fair value estimates for Johnson & Johnson's stock range from US$133 to US$243 per share, indicating varying investor perspectives on the company's future revenue and margin risks.
Risks and Considerations
Biosimilar Competition: The looming threat of biosimilars remains a significant concern for investors, potentially impacting revenue and margins.
Legal Challenges: Ongoing litigation related to talc products introduces additional financial uncertainties that stakeholders should monitor closely.
Investment Insights
Research and Analysis: Simply Wall St offers a comprehensive analysis of Johnson & Johnson, highlighting key rewards and warning signs that could influence investment decisions.
Market Trends: The article also touches on broader market opportunities, including emerging sectors like quantum computing and AI, suggesting potential investment avenues beyond established giants.
JNJ
$209.3+Infinity%1D
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 214.170
Low
176.00
Averages
207.26
High
230.00
Current: 214.170
Low
176.00
Averages
207.26
High
230.00
BofA
Neutral
maintain
$204 -> $220
2025-12-15
New
Reason
BofA
Price Target
$204 -> $220
2025-12-15
New
maintain
Neutral
Reason
BofA raised the firm's price target on Johnson & Johnson to $220 from $204 and keeps a Neutral rating on the shares. The firm, which believes J&J's premium-sector multiple "looks appropriate for its growth plus asset mix," is shifting its valuation basis to its new FY27 EPS estimate.
Morgan Stanley
Equal Weight
maintain
$190 -> $197
2025-12-12
New
Reason
Morgan Stanley
Price Target
$190 -> $197
2025-12-12
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Johnson & Johnson to $197 from $190 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
RBC Capital
Outperform
maintain
$209 -> $230
2025-12-11
New
Reason
RBC Capital
Price Target
$209 -> $230
2025-12-11
New
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Johnson & Johnson to $230 from $209 and keeps an Outperform rating on the shares after hosting an investor visit to the company's headquarters. Among the firm's positive takeaways is that JNJ's core MedTech business is poised to deliver mid-high single digit sales growth against a backdrop of positive healthcare utilization as the company has been focused on portfolio optimization and disciplined R&D spending on innovations, the analyst tells investors in a research note. The company's Immunology business is also on solid footing despite Stelara loss of exclusivity, the firm added.
Citi
Joanne Wuensch
Buy
upgrade
$215 -> $232
2025-12-11
New
Reason
Citi
Joanne Wuensch
Price Target
$215 -> $232
2025-12-11
New
upgrade
Buy
Reason
Citi analyst Joanne Wuensch raised the firm's price target on Johnson & Johnson to $232 from $215 and keeps a Buy rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
